血清lncRNA DLX6-AS1 Actinin-4表达与宫颈癌术后复发及预后的关系

doi:10.3969/j.issn.1006-6233.2022.10.021

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1330 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To study the relationship between the expressions of serum long non-coding RNA (lncRNA) DLX6-AS1 and actinin-4 in patients with cervical cancer and their relationship with recurrence and prognosis after radical resection of cervical cancer. Methods: A total of 120 cervical cancer patients who underwent radical resection of cervical cancer from February 2016 to February 2018 were selected as the research subjects (cervical cancer group),and 50 healthy individuals who underwent physical examination during the same period were selected as the control group.The cervical cancer group was divided into non-recurrence group (101 cases) and recurrence group (19 cases) according to the tumor recurrence and progression 3 years after operation.The expression of serum lncRNA DLX6-AS1 was detected by fluorescence real-time quantitative polymerase chain reaction,and the expression of serum actinin-4 was detected by enzyme-linked immunosorbent assay.Statistical analysis was performed to compare the relationship between the expression levels of serum lncRNA DLX6-AS1,actinin-4 and the clinicopathological characteristics of cervical cancer patients.At 3 years follow-up,Kaplan-Meier survival analysis was used to analyse the difference between serum lncRNA DLX6-AS1 and actinin-4 expression and postoperative prognosis of cervical cancer patients.The factors affecting postoperative recurrence of cervical cancer patients were analyzed. Results: Compared with the control group,the expression of serum lncRNA DLX6-AS1 and actinin-4 in the cervical cancer group was significantly higher (P<0.05).Pearson correlation analysis showed that the expression of serum lncRNA DLX6-AS1 and Actinin-4 in the cervical cancer group showed a significant positive correlation (r = 0.560,P = 0.000).There were significant differences in serum lncRNA DLX6-AS1 and Actinin-4 expression between patients with different FIGO stages,pathological grades,depth of interstitial invasion and lymph node metastasis(P<0.05).The 3-year progression-free survival rate and progression-free survival time were lower in the lncRNA DLX6-AS1 high expression group and Actinin-4 high expression group than in the low expression group ( All P<0.05).The pathological grade of low differentiation,FIGO stage IIA,high expression of lncRNA DLX6-AS1 and high expression of Actinin-4 were independent risk factors for recurrence of cervical cancer after radical cervical surgery (all P<0.05). Conclusion: Increased expression of serum lncRNA DLX6-AS1 and Actinin-4 in patients with cervical cancer is associated with postoperative recurrence of cervical cancer and may be a new serum marker for prognosis.

Key words： Long non-coding RNA DLX6-AS1 Actinin 4 Radical surgery for cervical cancer Recurrence

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2022.10.021 OR http://www.hbyxzzs.cn/EN/Y2022/V28/I10/1689

[1] 王瑾瑶,张年萍,白志强,等.1993年至2017年中国宫颈癌发病率和死亡率长期趋势的年龄-时期-队列模型分析[J].中国全科医学,2022,25(13):1564-1568.
[2] Small W,Bosch W R,Harkenrider M M,et al.NRG oncology/RTOG consensus guidelines for delineation of clinical target volume for intensity modulated pelvic radiation therapy in postoperative treatment of endometrial and cervical cancer:an update[J].Int Radiat Oncol Biol Phys,2021,109(2):413-424.
[3] Wang H,Niu X,Jiang H,et al.Long non-coding RNA DLX6-AS1 facilitates bladder cancer progression through modulating miR-195-5p/VEGFA signaling pathway[J].Aging (Albany NY),2020,12(16):16021-16034.
[4] Fang C,Li J,Deng T,et al.Actinin-4 as a diagnostic biomarker in serum of breast cancer patients[J].Med Sci Monit,2019,25(7):3298-3302.
[5] Park S,Kang M,Kim S,et al.α-actinin-4 promotes the progression of prostate cancer through the Akt/GSK-3β/β-catenin signaling pathway[J].Front Cell Dev Biol,2020,8(7):5885-5864.
[6] Xu Y,Zhang M,Zhang J,et al.Neoadjuvant chemotherapy increases the 5-year overall survival of patients with resectable cervical cancer:a systematic review and meta-analysis[J].Taiwan Obstet Gynecol,2021,60(3):433-441.
[7] 阿曼古丽,王英红.LncRNA SRA在宫颈癌患者血清中的表达及与预后的关系[J].中国妇产科临床杂志,2020,21(3):304-305.
[8] Zhao X,Wang J,Zhu R,et al.DLX6-AS1 activated by H3K4me1 enhanced secondary cisplatin resistance of lung squamous cell carcinoma through modulating miR-181a-5p/miR-382-5p/CELF1 axis[J].Sci Rep,2021,11(1):2101-2110.
[9] Xie F,Xie G,Sun Q.Long noncoding RNA DLX6-AS1 promotes the progression in cervical cancer by targeting miR-16-5p/ARPP19 axis[J].Cancer Biother Radiopharm,2020,35(2):129-136.
[10] Tian Y,Wang Y,Jia S.Knockdown of long noncoding RNA DLX6-AS1 inhibits cell proliferation and invasion of cervical cancer cells by downregulating FUS[J].Eur Rev Med Pharmacol Sci,2020,24(19):9771-9779.
[11] Zhao Z,Liang S,Sun F.LncRNA DLX6-AS1 promotes malignant phenotype and lymph node metastasis in prostate cancer by inducing LARGE methylation[J].Front Oncol,2020,10(7):1172-1179.
[12] Wang Q,Qin Q,Song R,et al.NHERF1 inhibits beta-catenin-mediated proliferation of cervical cancer cells through suppression of alpha-actinin-4 expression[J].Cell Death Dis,2018,9(6):668-674.
[13] Sugano T,Yoshida M,Masuda M,et al.Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive,HER2-negative,node-negative invasive breast carcinoma[J].Br Cancer,2020,122(12):1811-1817.
[14] Jung J,Kim S,An H,et al.α-Actinin-4 regulates cancer stem cell properties and chemoresistance in cervical cancer[J].Carcinogenesis,2020,41(7):940-949.
[15] Su W,Shen Y,Wang Y,et al.circPHIP promotes oral squamous cell carcinoma progression by sponging miR-142-5p and regulating PHIP and ACTN4 expression[J].Mol Ther Nucleic Acids,2020,23(7):185-199.